Navigation Links
Boston Scientific Announces Launch of PROMUS Element™ Platinum Chromium Stent System in Japan
Date:3/1/2012

NATICK, Mass., March 1, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces the launch of the PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent System in Japan.  The product was recently approved by the Ministry of Health, Labor and Welfare.  The PROMUS Element Stent System incorporates a platinum chromium (PtCr) alloy with an innovative stent design and an advanced catheter delivery system designed to provide physicians improved drug-eluting stent performance in treating patients with coronary artery disease.  The Company plans to begin marketing the product immediately in Japan.

"We are very pleased to launch the PROMUS Element Stent System to Japanese physicians and their patients," said Yusuke Naiki, President of Boston Scientific Japan.  "This everolimus-based stent system complements our broad coronary intervention portfolio and reinforces our global leadership in the drug-eluting stent market."

The PROMUS Element Stent uses a proprietary PtCr alloy designed specifically for coronary stenting, which enables enhanced visibility, less recoil, excellent conformability and higher radial strength.  It employs an advanced low-profile delivery system to enable precise stent placement across challenging lesions.  The everolimus drug and fluorinated copolymer used on the PROMUS Element Stent have been studied in multiple randomized clinical trials and registries.  The PROMUS Element Stent expands Boston Scientific's PtCr drug-eluting stent portfolio in Japan, which also includes the TAXUS® Element Paclitaxel-Eluting Platinum Chromium Coronary Stent System.

"This approval marks two important milestones for Boston Scientific," said Hank Kucheman, Chief Executive Officer of Boston Scientific.  "First, the PROMUS Element Stent platform is now approved in every major market wor
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015  Diomics, an innovator in ... Weissman , global financial executive, has joined Diomics, board ... more than 25 years of industry experience in broad ... as a managing director at Credit Suisse and JP ... Stanley/Dean Witter. "Diomics is on the forefront ...
(Date:6/1/2015)... Research and Markets  ( http://www.researchandmarkets.com/research/4lw2mn/global_a_dialyzer ) ... A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor ) ... The Global A Dialyzer Reprocessing Machine ... a professional and in-depth study on the current ... The report provides a basic overview of ...
(Date:6/1/2015)... BROOK, N.J. , June 1, 2015 /PRNewswire/ ... Food and Drug Administration (FDA) has accepted for ... for Anthim® (obiltoxaximab) for the treatment and prevention ... was submitted on March 20, 2015. Anthim is ... National Stockpile, the U.S. government,s repository of critical ...
Breaking Medicine Technology:Richard M. Weissman joins Diomics Board of Directors 2Global A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor) Industry Report 2014 - Development Trends Forecasts to 2020 2Global A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor) Industry Report 2014 - Development Trends Forecasts to 2020 3U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 2U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 3
... March 19 FluoroPharma Inc., a company,developing breakthrough ... (PET) market, announced commencement of Phase,I clinical trials ... the proposed studies. The Phase I trial is ... safety, distribution and dosimetry,of BFPET as a PET ...
... KNOLLS, N.J., March 19 Emisphere,Technologies, Inc. (Nasdaq: ... studies demonstrating that its proprietary eligen(R) technology,enhances the ... than were,used previously. The lower doses are believed ... the rate of absorption of B12 administered,with eligen(R) ...
Cached Medicine Technology:FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses 2Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses 3
(Date:6/1/2015)... June 02, 2015 The National ... Willey as a 2015-2016 inductee into its VIP ... with this prestigious distinction for leadership in safety, environment, ... networking organization exclusively for professional women, boasting more than ... "I’m pleased to present Lourinda with this important honor,” ...
(Date:6/1/2015)... 02, 2015 Dr. Robert ... Piedmont Physical Medicine & Rehabilitation, P.A., has published ... of stem cell therapy for knees, and highlights ... preferred alternative to arthroscopy or knee joint replacement. ... of Neuromusculoskeletal, Vascular and Regenerative Medicine, writes that ...
(Date:6/1/2015)... 01, 2015 Atagi Plastic Surgery and ... named an Ultherapy® Ultra Treatment Provider by ... Skin Aesthetics is one of only six practices in ... treatment provider. , Atagi Plastic Surgery and Skin ... area has led the practice to earn the distinction ...
(Date:6/1/2015)... 2015 The Muscular Dystrophy Association ... in participating in the sold out 2015 Bank ... secure guaranteed entry by signing up through the ... space is limited. , This national endurance program ... and abilities, and a supportive community of teammates, ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 Note: Dr. ... development in breast cancer prevention. , A phase III ... that postmenopausal women with ductal carcinoma in situ (DCIS) ... and prevention. , The study (NSABP B-35/NRG Oncology) looked ... completed the standard five-year treatment with tamoxifen to those ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Lourinda Willey, Owner and Principal of Lourinda R. Willey LLC, Into its VIP Professional Woman of the Year Circle 2Health News:New Article by Dr. Robert G. Schwartz of Piedmont Physical Medicine & Rehabilitation Looks at Benefits of Stem Cell Therapy for Knees 2Health News:New Article by Dr. Robert G. Schwartz of Piedmont Physical Medicine & Rehabilitation Looks at Benefits of Stem Cell Therapy for Knees 3Health News:Atagi Plastic Surgery and Skin Aesthetics Named Ultherapy® Ultra Treatment Provider 2Health News:Sold Out 2015 Bank of America Chicago Marathon and Marine Corps Marathon Entries Still Available through MDA Team Momentum 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 3
... complication that can occur in children affected by acute ... attack, pulmonary embolism and other cardiovascular diseases//. ... Italy by the Laboratory of Genetic and Environmental Epidemiology ... collaboration with the Haematology Division of the University of ...
... Prexige is said to be linked to an increased risk ... warned to exercise caution in its use.// ,The ... Prexige (generic name, lumiracoxib) available from Tuesday. The drug is ... it was found in 2004 that these group of drugs ...
... have suggested that cross-immunity created in response to infection ... //,by related serotypes thus leading to the waxing and ... help understand the pattern of this deadly mosquito-borne illness ... 1980s, there's been a sequential replacement of the dominant ...
... Indiana University School of Medicine it was found that ... the life span of those suffering from compromised immune ... the journal of Biological Chemistry. These proteins can be ... boost the patient’s immune system. The lead researcher Roman ...
... been criticized severely because a staff nurse has refused to send ... Mary Smith, 87 had an agonizing pain in her lower abdomen. ... replied that she could not have an ambulance and had to ... her. Then when the GP arrived he just gave her some ...
... minds of many cancer survivors. After treatment, as life ... makers now //,consider a chronic condition, survivors need to ... choices to ensure quality-of-life. This national movement, commonly referred ... year. ,Steps for Living (SFL), a nonprofit ...
Cached Medicine News:Health News:Thrombosis, a Serious Risk in Children with Leukemia 2Health News:New Arthritis Drug Linked to Increased Risk of Heart Attacks 2Health News:Waxing And Waning Of Dengue Epidemics Attributed To Cross-Immunity 2Health News:Waxing And Waning Of Dengue Epidemics Attributed To Cross-Immunity 3Health News:New Music Project Promotes Quality-of-Life After Cancer 2
... Easyfield is lightweight enough to shuttle ... carrying case. Designed with a goldmann standard ... fixed-point grid with 79 locations (including 30-2, ... and 3 different suprathresholds out to 30. ...
The Oculus easyfield is an exciting new compact perimeter to do automatic static perimetry up to 30 degrees eccentricity. It has been designed for the combined use as a visual field screener and peri...
... additional hardware and software features to meet ... clinics or teaching institutions. Standard with B/Y ... for experimental or clinical studies. Ethernet connection ... further tests including Flicker- and Color perimetry, ...
... Designed around the patented ... Octopus 301 sets the trend ... decade. Ideal for routine screening ... performance, accuracy and quality ...
Medicine Products: